Skip to content

The Impact of Oliceridine on Postoperative Catheter-Related Bladder Discomfort in Patients Undergoing Laparoscopic Radical Resection for Digestive Tract Tumors

The Impact of Oliceridine on Postoperative Catheter-Related Bladder Discomfort in Patients Undergoing Laparoscopic Radical Resection for Digestive Tract Tumors

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500102627
Enrollment
Unknown
Registered
2025-05-16
Start date
2025-06-01
Completion date
Unknown
Last updated
2025-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Catheter-related Bladder Discomfort

Interventions

Oliceridine Group:Supplemental dose of 2 mg oliceridine 30 min before surgery completion
postoperative analgesia via intravenous patient-controlled analgesia (PCA) pump: normal saline 100 mL containing oliceridine 0.2 mg/mL, ondansetron 0.32 mg/mL, background infusion rate 0.5 mL/h, PCA b
Sufentanil Group:Supplemental dose of 10 µg sufentanil 30 min before surgery completion
postoperative analgesia via intravenous patient-controlled analgesia (PCA) pump: normal saline 100 mL containing sufentanil 1 µg/mL, ondansetron 0.32 mg/mL, background infusion rate 0.5 mL/h, PCA bolu

Sponsors

DEYANG PEOPLE'S HOSPITAL
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Male age 18~75 years old; 2. American Society of Anesthesiologists (ASA) is graded as II~III; 3. Elective laparoscopic radical resection of the digestive system (including gastric surgery, right hemicolectomy, left hemicolectomy, sigmoiidrectomy, rectal surgery, left hemihepatectomy); 4. Catheterization with a 14 or 16 Fr Foley catheter; 5BMI 18~30 kg/m²; 6. Inability to tolerate pain as assessed by a doctor (NRS score >=4 points); 7. Those who voluntarily participate in the pilot study, can understand the research process, communicate effectively with the researchers, and have signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Hypersensitivity to any study medication; 2. Concomitant use of medications with known interactions with magnesium sulfate (e.g.lithium); 3. Severe hepatic impairment (Child-Pugh class B or C); 4. Renal dysfunction (glomerular filtration rate <30 mL/min.1.73 m²); 5. Failed urinary catheterization.

Design outcomes

Primary

MeasureTime frame
Incidence of urinary catheter-related bladder discomfort score >= 1 at full patient wakefulness (Modified Observer"s Assessment of Alertness/Sedation score = 5);

Secondary

MeasureTime frame
Incidence and severity of catheter-related bladder discomfort ;Intraoperative remifentanil consumption;Quality of Recovery-15 score ;

Countries

China

Contacts

Public ContactXianjie Zhang

Deyang People's Hospital

zxianjiemazui@163.com+86 183 2808 1058

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026